We are sharing this news release from Facio, the Netherlands-based biotech founded by FSHD advocates and business leaders with the sole mission of developing treatments for FSHD. In this story, Facio announces that it has identified drug-like molecules that show promise in repressing DUX4, the gene believed to be a key driver of the disease. The story describes some of the biological criteria that company is seeking to ensure an effective, safe treatment, and notes that the compounds it has identified have not previously been reported in the published scientific literature, nor do they include “re-purposed drugs” that are currently on the market for other uses.
Disclaimer: The release does not include peer-reviewed data or scientific citations so readers cannot evaluate the validity of specific claims made in the release.
Read the full release here.